Sistema PJSFC (SSA)
Sistema PJSFC: Sistema completes merger of OBL Pharm and Binnopharm
14-Oct-2019 / 09:45 MSK
Dissemination of a Regulatory Announcement that contains inside information
according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Sistema completes merger of OBL Pharm and Binnopharm
Moscow, 14 October 2019. - Sistema PJSFC ("Sistema") (LSE: SSA, MOEX: AFKS),
a publicly traded diversified Russian holding company, announces the
completion of the merger of pharmaceutical assets JSC Pharmaceutical
Enterprise Obolenskoe ("OBL Pharm") and JSC Binnopharm ("Binnopharm"). The
merged company will operate under the brand Alium.
As a result of Sistema's participation in an additional issue of OBL Pharm
shares, Sistema's effective stake in the company increased from 12.8% to
26.3%. VTB Bank's effective stake in OBL Pharm now stands at 38.5%, while
the total stake owned by the consortium of investors including the Russian
Direct Investment Fund ("RDIF"), the Russia-China Investment Fund (RCIF,
which was created by RDIF and China Investment Corporation) and leading
Middle Eastern funds is 23.0%. Sistema paid for its additional shares of OBL
Pharm using the 88.7% of Binnopharm shares that it owned.[1]
The merger of OBL Pharm and Binnopharm created pharmaceuticals holding
Alium, one of Russia's largest pharma companies in the commercial segment.
Alium's total production area exceeds 70,000 sq m and includes four
high-tech facilities in Moscow and the Moscow region. The company's
diversified product portfolio comprises approximately 200 drugs used across
therapeutic areas including respiratory, nervous and gastrointestinal
systems, cardiology, infectious diseases and colds as well as pain relief.
***
Sistema PJSFC is a publicly-traded diversified Russian holding company
serving over 150 million customers in the sectors of telecommunications,
high technology, financial services, retail, paper and packaging,
agriculture, real estate, tourism and medical services. The company was
founded in 1993. Revenue in 2018 was RUB 777.4 bn; total assets equalled RUB
1.5 trn as of 31 December 2018. Sistema's global depositary receipts are
listed under the "SSA" ticker on the London Stock Exchange. Sistema's
ordinary shares are listed under the "AFKS" ticker on the Moscow Exchange.
Website: www.sistema.com [1]
***
For further information, please visit www.sistema.com [1] or
contact:
Investor Relations Public Relations
Nikolai Minashin Sergey Kopytov
Tel: +7 (495) 730 66 00 Tel.: +7 (495) 228 15 32
n.minashin@sistema.ru kopytov@sistema.ru
=---------------------------------------------------------------------------
[1] As part of the process of merging OBL Pharm and Binnopharm, Sistema
increased its stake in Binnopharm to 88.7% by acquiring 14.7% of the company
from minority shareholders.
ISIN: US48122U2042
Category Code: MSCM
TIDM: SSA
LEI Code: 213800JSZ2UUK4QQK694
Sequence No.: 23264
EQS News ID: 889435
End of Announcement EQS News Service
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=8dbdb321a88e3508530119f5e3de64d2&application_id=889435&site_id=vwd&application_name=news
(END) Dow Jones Newswires
October 14, 2019 02:45 ET (06:45 GMT)
